Literature DB >> 15908450

Endothelial cell co-stimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA.

Javier Mestas1, Steve P Crampton, Toshiyuki Hori, Christopher C W Hughes.   

Abstract

Human endothelial cells (ECs) constitutively express OX40L and co-stimulate memory CD4(+) T cell proliferation that is dependent upon OX40-OX40L interaction. In vivo, OX40 prolongs T cell survival; however, an unanswered question is whether it can also prolong synthesis of proliferation-sustaining cytokines such as IL-2. Here we show that EC co-stimulation results in the secretion of T cell IL-2, IL-3 and IFN-gamma and that in the absence of OX40 signals synthesis largely ceases by 12-18 h, but is prolonged up to 60 h in the presence of OX40 signaling. Blocking OX40-mediated cytokine expression at later times suppresses T cell proliferation and this can be overcome by addition of exogenous IL-2. We find that OX40 signaling has discrete effects on T cell activation as it does not affect expression of IL-10, CD25, CD69 or soluble IL-2R. Also, OX40 does not appear to alter IL-2 transcription, but rather acts to stabilize a subset of cytokine mRNAs, increasing their half-lives by 3-6-fold. We further show that OX40L induces activation of p38 mitogen-activated protein kinase (MAPK) and phosphotidyl-inositol-3-kinase (PI3K) in T cells, and using specific inhibitors, we find that increased mRNA half-life is dependent upon both these pathways but is independent of c-jun-N-terminal kinase (JNK). Thus, EC co-stimulation through OX40 leads to prolonged T cell cytokine synthesis and enhanced proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908450     DOI: 10.1093/intimm/dxh255

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  21 in total

Review 1.  Participation of blood vessel cells in human adaptive immune responses.

Authors:  Jordan S Pober; George Tellides
Journal:  Trends Immunol       Date:  2011-10-24       Impact factor: 16.687

Review 2.  Post-transcriptional control of the interferon system.

Authors:  Khalid S A Khabar; Howard A Young
Journal:  Biochimie       Date:  2007-02-24       Impact factor: 4.079

Review 3.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 4.  Roles of OX40 in the pathogenesis and the control of diseases.

Authors:  Toshiyuki Hori
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

5.  Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcεRI-dependent mast cell degranulation.

Authors:  Riccardo Sibilano; Giorgia Gri; Barbara Frossi; Claudio Tripodo; Ryo Suzuki; Juan Rivera; Andrew S MacDonald; Carlo E Pucillo
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

Review 6.  T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells?

Authors:  Benjamin Wilde; Marielle Thewissen; Jan Damoiseaux; Pieter van Paassen; Oliver Witzke; Jan Willem Cohen Tervaert
Journal:  Arthritis Res Ther       Date:  2010-02-24       Impact factor: 5.156

Review 7.  B cell regulation of anti-tumor immune response.

Authors:  Yu Zhang; Richard Morgan; Eckhard R Podack; Joseph Rosenblatt
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 8.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

9.  Blockade of OX40-ligand after initial triggering of the T helper 2 response inhibits mercuric chloride-induced autoimmunity.

Authors:  Iain A M MacPhee; Hideo Yagita; David B G Oliveira
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

Review 10.  OX40, OX40L and Autoimmunity: a Comprehensive Review.

Authors:  Gwilym J Webb; Gideon M Hirschfield; Peter J L Lane
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.